Associations Between Depression, Anxiety, and Multiple Disease Outcomes: A Phenotype x Phenome-Wide Association Study in Electronic Health Records

Introduction

Although anxiety and depression are typically differentiated in specialty mental health settings, these diagnoses are frequently comorbid [1]. Pharmacologically, the two disorders are treated similarly with agents chiefly active on the serotoninergic system. Genetic studies further suggest almost complete overlap between anxiety and depression [2, 3]. However, despite these similarities, and the consequent hypotheses of a shared etiology [4–6], we continue to have a limited understanding of why certain individuals develop anxiety disorders, others develop depressive disorders, and many develop both.

Heterogeneity, both between and within each of these disorders, contributes to the difficulty of characterizing them both genetically and neurobiologically. Under the Research Domain Criteria (RDoC) project, depression has been characterized as a disorder of impaired reward response, learning, and valuation [7, 8]. By contrast, anxiety has been conceptualized in RDoC as a dysfunction of threat detection [7, 8]. Clinically, however, there may be several overlapping domains. Anxiety symptoms have been incorporated into some diagnostic criteria for depression [9]. Other clinical symptoms such as psychomotor disturbances, appetite alterations, sleep patterns, and suicidal behaviors have also been incorporated into recent work attempting to identify genetically distinct depression subtypes with the hope of identifying neurobiological therapeutic targets [10].

Because depression and anxiety are both common mental disorders, they have been widely studied in medical settings [11–14]. Both disorders have been found to be associated with functional impairment and adverse outcomes across multiple settings ranging from increased disability and days off from work [14] to elevated risk for cardiovascular events and lower rates of cardiovascular recovery [12]. The distinctions between symptomatic phenotypes within and between these two disorders are also medically meaningful. Some evidence suggests depression and anxiety vary in the strength of their correlations with specific physical conditions. Compared to anxiety, for example, depression has a stronger correlation with obesity, while metabolic and inflammatory conditions are strongly correlated with hyperphagia, hypersomnia, and lethargy [11]. Similarly, skin diseases have been associated with panic severity, but not with depression severity [15]. As patients age, and physical health declines, new associations may further emerge between a patient’s mental health symptoms and physical conditions.

While factors such as the timing of onset have been found to differentiate depression subtypes [10, 16], it has not been frequently incorporated into exploratory investigations. This is partly due to the design of many prior studies, which have addressed specific hypotheses regarding single conditions or sought to describe lifetime risk [17]. However, temporal factors, such as the age at onset of illness or the timing of illness onset relative to the onset of comorbidity, can be inform understanding of clinical course. For example, anxiety disorders are much more likely to present at younger ages and to predate diagnosis of depressive disorders [18, 19]; however, new anxiety, particularly presenting in older populations, may be indicative of new cognitive impairment or dementia [16].

The relationship between mental and physical disorders is often further complicated by bidirectionality. Observed comorbidity rates of depression and anxiety exceed what would have been predictable by heritability suggesting common environmental stressors as well as common genetic preloading [10, 19]. Adverse health outcomes can also themselves act as stressors and contribute psychologically and physiologically to symptoms of depression and anxiety [20, 21]. With these considerations in mind, we conducted an exploratory analysis to identify differences in the clinically observable phenome, representing a wide variety of mental and physical health disorders, between patient with diagnoses of depression, anxiety, or both. Using the Mayo Clinic Biobank, we performed a phenotype x phenome-wide association study (Phe²WAS). PheWAS is an agnostic approach that originally involved testing for association between genetic variation or genetic risk across the clinical phenome observed in the electronic health record (EHR) as measured using diagnostic phecodes [17, 22]. Instead of using genetic data as the predictor, the Phe²WAS approach uses another phenotype as the predictor to identify phenotypic correlations across the EHR with the phenotype of interest or, if a binary phenotype, test for differences between two different groups of patients. We defined several clinical phenotypes within the broader categories of depression and anxiety (isolated depression, isolated anxiety, and comorbid depression and anxiety) and applied the Phe²WAS approach to test for differences between the clinical groupings across the EHR phenome (i.e. phecodes). We also examined the impact of temporality of other diagnoses vs. the anxiety/depression diagnoses on the Phe²WAS as a means of further differentiating the clinical groupings of isolated anxiety and isolated depression.

Methods

Data for this study were derived from the EHR of participants in the Mayo Clinic Biobank [23]. All patients in the study gave informed consent for biobank research and the study was approved by the Mayo Clinic Institutional Review Board and the Mayo Clinic Biobank Access Committee.

The EHR includes clinical data as well as data on demographics, medications/prescriptions, laboratory values, billing codes from the International Classification of Diseases, 9^th and 10^th editions (ICD-9-CM and ICD-10-CM), and Current Procedural Terminology (CPT) codes [24]. We mapped ICD-9-CM and ICD-10-CM codes to phecodes (i.e. higher order group of diagnoses) as described and validated by the Phecode map 1.2b1 [25]. For the current study, we included all available EHR data from before April 6, 2020. Patients were defined as having a given phecode diagnosis if they had at least 2 instances of codes from that phecode in their EHR with the index date of each code defined as the first instance in the HER.

Results

We identified 14994 patients from the Mayo Clinic Biobank with at least 2 codes for anxiety or depression. Of these, 5246 (35.0%) had isolated depression, 3213 (21.4%) had isolated anxiety, and 6535 (43.6%) had comorbid depression and anxiety. Proportions of isolated versus comorbid diagnosis differed between men and women: 46.9% of women in our sample were diagnosed with comorbid depression and anxiety compared to 36.1% of men. The sample was older (mean current age 66.4 years) and mostly non-Hispanic (95.0%), white (90.2%), and female (69.3%) with no large differences in demographics among the different diagnostic groups (Table 1). Of note, patients with isolated anxiety and isolated depression were diagnosed at an older age (mean age of 57.5 and 56.1 years old, respectively) than those with comorbid anxiety and depression (mean age of 52.3 and 50.2 years old, respectively). Furthermore, while those with isolated anxiety and depression had fewer total ICD codes in their record (mean=514 and 585, respectively) compared to patients with the comorbidity (mean=848 codes), all groups had similar length of record and median age of record indicating that those with the comorbidity could have higher rates of other comorbid conditions as well.

Phe²WAS of comorbid depression and anxiety versus those with only one disorder

In comparing the lifetime diagnostic phecodes of patients with comorbid depression and anxiety to those with isolated depression or anxiety (Figure 2), patients with the comorbidity were more likely to have other mental health disorders, substance use disorders, sleep problems, digestive issues, and symptoms. In particular, among many codes, rates of insomnia (OR=1.70; p=1e-39), suicidal ideation or attempt (OR=4.87; p=5e-38), post-traumatic stress disorder (OR=3.5; p=8e-32), substance use disorders (OR=2.15; p=4e-23), alcohol use disorder (OR=2.02; p=2e-22), chronic pain syndrome (OR=1.72; p=2e-16), GERD (OR=1.32; p=2e-13), irritable bowel syndrome (OR=1.42; p=2e-9) and myalgia and myositis (OR=1.4; p=2e-16) were higher in those with the comorbidity than those with isolated anxiety or depression.

• Download figure
• Open in new tab

Figure 1.

Manhattan plot comparing the phenome of those with isolated depression to those with isolated anxiety.

Triangles with single point upward indicate phecodes more commonly observed in patients with isolated depression than in patients with isolated anxiety. Triangles with single point downwards indicate phecodes more common in patients with isolated anxiety than in those with isolated depression. Associations are adjusted for current age, self-reported gender, race, and ethnicity, length of EHR record, median age of all ICD codes in a patient’s record, and total number of ICD codes. Participants with comorbid depression and anxiety, and those with neither condition, are excluded from this analysis.

• Download figure
• Open in new tab

Figure 2.

Manhattan plot comparing the lifetime phenome of those with comorbid depression and anxiety to those with isolated depression or anxiety.

Triangles with single point upward indicate phecodes more commonly associated with comorbid depression and anxiety as compared to either isolated depression or isolated anxiety. Triangles with single point downwards indicate phecodes more commonly occurring with either isolated depression or isolated anxiety than with comorbid depression and anxiety. Analyses are adjusted for current age, self-reported gender, race, and ethnicity, length of EHR record, median age of record, and total number of ICD codes.

Discussion

In contrast to prior studies, we defined phenotypes of isolated depression and isolated anxiety in addition to those with comorbid depression and anxiety [17, 18]. Compared to patients with isolated anxiety, patients with isolated depression had a higher frequency of metabolic abnormalities such as obesity and type II diabetes, as well as sleep apnea and hypersomnia. Differences between rates of obesity, schizophrenia, and neurological disorders were especially pronounced for diagnoses that were made after the initial depression or anxiety diagnosis. By contrast, the isolated anxiety group had significant overlaps with dermatologic diagnoses such as benign neoplasms and degenerative skin disorders, as well as cardiac symptoms such as palpitations and dysrhythmia; these differences were especially pronounced for medical diagnoses made before the first diagnosis of depression or anxiety.

These findings have several implications for our understanding of depression and anxiety and their relationships with other organ systems. First, consistent with prior research, we found a subset of patients with both depressive and gastrointestinal disorders [28–31]. The autonomic nervous system and serotonergic systems are implicated in gastrointestinal functions: gastric smooth muscle cells express 5-HT1 and 5-HT2 receptors where serotonin induces contractions in the gastric fundus and activity at 5-HT3 receptors caused gastric relaxation and accelerated intestinal transit [32, 33]. The common gastrointestinal side effects associated with SSRI antidepressants are illustrative of this relationship, however, so too are reports that ondansetron, a 5-HT3 receptor antagonist, improves depressive symptoms [32, 34]. These, at times, contradictory claims may suggest that multiple phenotypes occur within the subpopulation of patients presenting with co-occurring depressive and gastrointestinal disorders, and that perhaps even within individuals, relationships between a given set of symptoms and single neurotransmitter activity may be nonlinear. Our findings suggest that despite the potentially extensive relationship between central nervous and gastrointestinal systems, there is also some specificity and that patients with concurrent depression and anxiety appear to be at particular risk, which may narrow the set of potential genetic or molecular mechanisms involved.

Second, a less explored relationship between anxiety and skin disorders also implicates autonomic nervous system and serotonergic responses [35–37]. 5-HT2A is found in the upper epidermis of skin and 5-HT3 is expressed in the basal epidermal layer [38, 39]. Topical doxepin, used orally as an antidepressant, has been used to treat cold urticaria [40]. Our study describes a phenotype of concurrent isolated anxiety and skin disorders. Although it is possible that temperamental anxiety might provoke treatment seeking, it is significant that we observed a specific association with dermatologic diagnoses over other previously reported associations between anxiety and conditions that might mimic anxiety symptoms such as asthma [41, 42]. Similarly, although a variety of conditions such as a positive screening mammogram or prostate-specific antigen, might provoke reactive anxiety, the association with anxiety and skin conditions appears especially strong. Although inflammation has been generally implicated in the association of skin disorders with psychiatric symptoms, inflammation is systemic [5]. Thus, we add to the literature on phenotypic specificity.

Third, we further describe a previously characterized phenotype involving isolated depression associated with obesity and sleep apnea [11]. Compared to the comorbid depression group, the isolated depression group exhibited lower concurrent psychiatric risk. However, isolated depression diagnosis preceded obesity and related chronic health sequelae [12, 17]. Although we cannot causally attribute obesity to isolated depression, the diagnosis of depression may present a clinical opportunity for intervention prior to the development of other serious health conditions.

Fourth, associations of isolated depression with schizophrenia or neurological disorders were particularly pronounced relative to isolated anxiety in the period after first depression diagnosis. Prodromal depression has been described in schizophrenia and neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and vascular dementia [43–45]. Given the literature on the emergence of depression following neurological insults such as stroke or traumatic brain injury [46, 47], the strength of this temporal relationship between depression and neurological illness may be surprising, however, the population prevalence of depressive symptoms is high relative to that of specific neurological diagnoses or schizophrenia [48–50]. Possible initial misattribution of depressive symptoms to a primary mood disorder can also impact clinical care for the patients diagnosed with these disorders.

The results from these Phe²WAS analyses indicate that comorbid diagnoses of depression and anxiety are highly associated with many other psychiatric conditions including suicidal behaviors, substance use disorders, and personality disorders, even compared to those with isolated depression or anxiety, which is consistent with prior literature [17, 51, 52]. Among patients with depression diagnoses, those with comorbid depression and anxiety still outnumbered isolated depression, thus it is not surprising that aggregated studies conducted with samples of patients with depression are dominated by this subset. Depression as compared to anxiety was associated with gastroesophageal reflux, esophagitis, and gastritis, which parallels previous studies of depression compared to controls [17], though the rates of these conditions were even higher among those with comorbid depression and anxiety.

Most patients with depression or anxiety presented with either isolated depression or isolated anxiety. In previous studies, the reported rate of comorbid anxiety with depression has been as high as 85% of patients with depression and 90% of patients with anxiety [1]. However, our estimates are not out of line with estimates from other biobank samples [10]. Because the average median record length was 8.2 years, one explanation for this discrepancy is that, relative to surveys, EHRs are less sensitive at detecting lifetime psychiatric diagnoses. However, the phenotypic profiles of patients with isolated depression and isolated anxiety differed significantly from those with both depression and anxiety suggesting that these phenotypes correspond to distinct risk groups [53]. This aligns with a recent genetic study of depression, anxiety and their comorbidity, which showed independent depression and anxiety polygenic contributions to the comorbidity. Relative to prior analyses of epidemiological samples of non-elderly individuals, aged 15 to 54 years [18, 19], our sample was also older, with a median age of 66.4 years old. Some studies of older individuals have described both decreasing rates of depression and anxiety with increasing age and decreasing rates of comorbidity [16, 54]. Presenting constellations of depression and anxiety symptoms change with increasing age, reflecting cohort factors such as healthy survivor bias, social factors such as reactions to a loss of physical independence or social connections, and biological factors such as psychiatric symptoms of age-related cognitive decline [16, 54–56]. Our study results may reflect the evolving heterogeneity of depression and anxiety across the adult lifespan.

Limitations

This study has several limitations. First, our analysis was based on data from the Mayo Clinic Biobank, which represents a selective population of older adults of primarily European descent with higher-than-average levels of education [57]. Second, this analysis, which examines phenotypes from the EHR, is limited by length of record, selection into treatment, and other recording variables. This limits the examination of depression/anxiety onset, which often occurs at ages younger than those captured in our EHR. Third, although our final sample included 14,994 observations, we were restricted by sample size to investigating associations between relatively prevalent conditions. As such, we cannot comment on granular relationships between specific diagnoses. Fourth, our analysis was limited to phenotypes. Although we attempted to elucidate temporal clinical presentations of patients, we cannot use these findings to draw direct causal inferences and therefore view the results as exploratory.

Conclusions

PheWAS approaches, which invert the idea of genome-wide association studies, have been successful in demonstrating that specific genetic variations are associated with multiple traits [22]. Here, we leveraged this approach to instead examine associations with clinical groups of patients with depression and anxiety by using a phenotype, rather than a genotype, as a predictor of multiple clinical conditions derived from the EHR (Phe²WAS). The current results provide several interesting perspectives on the clinical landscape of depression and anxiety. Patients with comorbid depression and anxiety are a well-characterized psychiatric patient population. Due to their level of psychiatric risk, this group is also the most likely to present for mental health treatment at a relatively early age. By contrast, patients with isolated depression or anxiety may differentially present to primary care or a medical specialist, such as a cardiologist or a dermatologist. These differences have the potential to affect recruitment into clinical research and thus affect the generalizability of the results [58]. Learning from broad descriptive cohorts across service settings could help us better understand clinical heterogeneity, improve generalizability of diagnostic characterizations, and offer better treatments to patients with these common psychiatric disorders.